NLY 2023 Annual Report

ANNALY CAPITAL MANAGEMENT, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (dollars in thousands) For The Years Ended December 31, 2023 2022 2021 Preferred stock Beginning of period $ 1,536,569 $ 1,536,569 $ 1,536,569 End of period $ 1,536,569 $ 1,536,569 $ 1,536,569 Common stock Beginning of period $ 4,683 $ 3,649 $ 3,496 Issuance 315 1,031 152 Stock-based award activity 3 3 1 End of period $ 5,001 $ 4,683 $ 3,649 Additional paid-in capital Beginning of period $ 22,981,320 $ 20,324,780 $ 19,761,304 Issuance 673,378 2,634,969 552,063 Stock-based award activity 17,693 21,571 11,413 End of period $ 23,672,391 $ 22,981,320 $ 20,324,780 Accumulated other comprehensive income (loss) Beginning of period $ (3,708,896) $ 958,410 $ 3,374,335 Unrealized gains (losses) on available-for-sale securities 580,680 (8,204,542) (2,419,618) Reclassification adjustment for net gains (losses) included in net income (loss) 1,792,816 3,537,236 3,693 End of period $ (1,335,400) $ (3,708,896) $ 958,410 Accumulated deficit Beginning of period $ (9,543,233) $ (9,653,582) $ (10,667,388) Net income (loss) attributable to Annaly (1,643,171) 1,725,325 2,389,896 Dividends declared on preferred stock (1) (141,676) (110,623) (107,532) Dividends and dividend equivalents declared on common stock and stock-based awards (1) (1,294,688) (1,504,353) (1,268,558) End of period $ (12,622,768) $ (9,543,233) $ (9,653,582) Total stockholder’s equity $ 11,255,793 $ 11,270,443 $ 13,169,826 Noncontrolling interests Beginning of period $ 98,983 $ 25,499 $ 13,480 Net income (loss) attributable to noncontrolling interests 4,714 1,095 6,384 Equity contributions from (distributions to) noncontrolling interests (14,399) 72,389 5,635 End of period $ 89,298 $ 98,983 $ 25,499 Total equity $ 11,345,091 $ 11,369,426 $ 13,195,325 (1) Refer to the “Capital Stock” Note for dividends per share for each class of shares. See notes to consolidated financial statements. ANNALY CAPITAL MANAGEMENT, INC. AND SUBSIDIARIES Financial Statements F-5

RkJQdWJsaXNoZXIy NDQ4NTc1